Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

CTXR PEER ANALYSIS

Citius Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

CTXRCitius Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
CTXRIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
CTXR-72.5%RTALB+24.1%
Year-to-Date (YTD)
CTXR-21.8%RTALB+5.0%
1-Year
Split-adjusted
CTXR-72.5%VOR-47.4%BCAB-75.6%SGMO-86.7%ATNM-33.3%OTLK-20.2%
Year-to-Date (YTD)
CTXR-21.8%VOR+53.7%BCAB-83.9%SGMO-82.4%ATNM-29.3%OTLK-10.1%

Key Metric Comparison

P/E

Lower is better
CTXR—RTALB4.89Median 17.81

ROE

Higher is better
CTXR-75.6%RTALB15.1%Median -47.5%

Net Margin

Higher is better
CTXR-823.3%RTALB136.3%Median -125.7%

Revenue Growth

Higher is better
CTXR1,699.4%RTALB24.0%Median 5.1%

P/E

Lower is better

ROE

Higher is better
CTXR-75.6%VOR—BCAB—SGMO—ATNM-167.7%OTLK—Median -47.5%

Net Margin

Higher is better
CTXR-823.3%VOR—BCAB-2,530.9%SGMO-356.9%ATNM-26,078.9%OTLK-18,297.5%Median -125.7%

Revenue Growth

Higher is better
CTXR1,699.4%VOR-100.0%BCAB-81.8%SGMO-45.8%ATNM-88.9%OTLK-2.1%Median 5.1%

All Metrics

Valuation
MetricCTXRRTALBInd. Median
P/E—4.8917.81
P/B0.22●0.613.49
EV/EBITDA—74.6114.92
P/S2.42●6.6710.89
Financial Health
MetricCTXRRTALBInd. Median
Current Ratio0.581.21●5.90
Debt/Equity1.3%1.2%●10.9%
NetDebt/EBITDA0.07●0.901.15
Profitability
MetricCTXRRTALBInd. Median
Net Margin-823.3%136.3%●-125.7%
ROE-75.6%15.1%●-47.5%
ROA-36.4%13.1%●-35.8%
EBITDA Margin-996.7%9.0%●-105.8%
Growth + Dividend
MetricCTXRRTALBInd. Median
Rev. Growth1,699.4%●24.0%5.1%
NI Growth—134.0%12.1%
Div. Yield—0.0%0.2%
Payout—0.0%0.0%
Valuation
MetricCTXRVORBCABSGMOATNMOTLKInd. Median
P/E——————17.81
P/B0.22-0.06-0.18-1.52●13.03-1.253.49
EV/EBITDA—-1.07————14.92
P/S2.42—3.440.83●333.55108.5910.89
Financial Health
MetricCTXRVORBCABSGMOATNMOTLKInd. Median
Current Ratio0.5831.15●0.150.705.890.545.90
Debt/Equity1.3%-2.0%-16.3%-102.0%●65.9%-93.8%10.9%
NetDebt/EBITDA0.07-1.09●-0.090.071.79-0.311.15
Profitability
MetricCTXRVORBCABSGMOATNMOTLKInd. Median
Net Margin-823.3%—-2,530.9%-356.9%●-26,078.9%-18,297.5%-125.7%
ROE-75.6%●———-167.7%—-47.5%
ROA-36.4%●-286.7%-216.1%-168.8%-41.1%-297.6%-35.8%
EBITDA Margin-996.7%—-2,389.5%-339.9%●-25,150.0%-18,634.1%-105.8%
Growth + Dividend
MetricCTXRVORBCABSGMOATNMOTLKInd. Median
Rev. Growth1,699.4%●-100.0%-81.8%-45.8%-88.9%-2.1%5.1%
NI Growth——————12.1%
Div. Yield——————0.2%
Payout——————0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on CTXR

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.